Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
2023年11月10日 - 6:30AM
Vivos Therapeutics, Inc. (“Vivos” or the “Company”)
(NASDAQ: VVOS), a medical technology company focused on
developing innovative treatments for patients suffering from
dentofacial abnormalities and/or mild-to-moderate obstructive sleep
apnea (OSA) and snoring in adults, today announced it plans to
release its third quarter 2023 financial results after market close
on Tuesday, November 14, 2023. The Company will conduct a
conference call at 5:00 p.m. (Eastern Time) the same day to review
the results and provide an overview of the Company’s recent
milestones and developments.
To access Vivos’ investor conference call,
please dial (844) 826-3033, or for international callers, (412)
317-5185. A replay will be available shortly after the call and can
be accessed by dialing (844) 512-2921, or for international
callers, (412) 317-6671. The passcode for the live call and the
replay is 10184114. The replay will be available until November 28,
2023.
A live webcast of the conference call can be
accessed on Vivos’ website at https://vivos.com/investor-relations.
An online archive of the webcast will be available on the Company’s
website for 30 days following the call.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a
medical technology company focused on developing and
commercializing innovative diagnostic and treatment methods for
patients suffering from breathing and sleep issues arising from
certain dentofacial abnormalities such as mild-to-moderate
obstructive sleep apnea (OSA) and snoring in adults. The Vivos
Method represents the first clinically effective nonsurgical,
noninvasive, nonpharmaceutical and cost-effective solution for
treating mild to moderate OSA. It has proven effective (within the
scope of the FDA cleared uses) in approximately 40,000 patients
treated worldwide by more than 1,850 trained dentists.
The Vivos Method includes the Vivos Complete
Airway Repositioning and/or Expansion (CARE) appliance therapy and
associated protocols that alter the size, shape and position of the
soft tissues that comprise a patient’s upper airway and/or palate.
The Vivos Method opens airway space and may significantly reduce
symptoms and conditions associated with mild-to-moderate OSA, such
as lowering Apnea Hypopnea Index scores. Vivos also markets and
distributes SleepImage diagnostic technology under its VivoScore
program for home sleep testing in adults and children. The Vivos
Integrated Practice (VIP) program offers dentists training and
other value-added services in connection with using The Vivos
Method.
Cautionary Note Regarding Forward-Looking
Statements
This press release, the conference call referred
to herein, and statements of the Company’s management made in
connection therewith contain “forward-looking statements” (as
defined in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended)
concerning future events. Words such as “may”, “should”, “expects”,
“projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”,
“goal”, “estimates” and variations of such words and similar
expressions are intended to identify forward-looking statements.
These statements involve known and unknown risks and are based upon
several assumptions and estimates, which are inherently subject to
significant uncertainties and contingencies, many of which are
beyond Vivos’ control. Actual results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially
include, but are not limited to, the risk factors described in
Vivos’ filings with the Securities Exchange Commission (“SEC”).
Vivos’ filings can be obtained free of charge on the SEC's website
at www.sec.gov. Except to the extent required by law, Vivos
expressly disclaims any obligations or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Vivos' expectations with
respect thereto or any change in events, conditions, or
circumstances on which any statement is based.
Vivos Investor Relations and Media
Contact:Julie GannonInvestor Relations
Officer720-442-8113jgannon@vivoslife.com
Vivos Therapeutics (NASDAQ:VVOS)
過去 株価チャート
から 5 2024 まで 6 2024
Vivos Therapeutics (NASDAQ:VVOS)
過去 株価チャート
から 6 2023 まで 6 2024